Literature DB >> 1424647

Ocular surface residence times of artificial tear solutions.

G R Snibson1, J L Greaves, N D Soper, J M Tiffany, C G Wilson, A J Bron.   

Abstract

Solutions of hydroxypropylmethylcellulose (HPMC) and polyvinyl alcohol (PVA) are widely used as artificial tears. However, their usefulness is limited by the short duration of their effect. Dilute sodium hyaluronate (SH) solutions exhibit non-Newtonian rheology with high viscosities at low shear rates, which would be expected to enhance their ocular surface residence time. Using quantitative gamma scintigraphy, estimates of the ocular surface residence times of 0.3% HPMC, 1.4% PVA, and 0.2% SH were made in six patients with keratoconjunctivitis sicca. The sodium hyaluronate solution had a mean half-life on the ocular surface of 321 s, significantly longer than hydroxypropylmethylcellulose (44 s; p = 0.012) and polyvinyl alcohol (39 s; p = 0.013).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424647     DOI: 10.1097/00003226-199207000-00003

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  20 in total

1.  Interfacial interaction between transmembrane ocular mucins and adhesive polymers and dendrimers analyzed by surface plasmon resonance.

Authors:  I Bravo-Osuna; M Noiray; E Briand; A M Woodward; P Argüeso; I T Molina Martínez; R Herrero-Vanrell; G Ponchel
Journal:  Pharm Res       Date:  2012-05-08       Impact factor: 4.200

2.  Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye.

Authors:  Pasquale Aragona; Vincenzo Papa; Antonio Micali; Marcello Santocono; Giovanni Milazzo
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

3.  Use of Collagen Binding Domains to Deliver Molecules to the Cornea.

Authors:  Jes K Klarlund; Jake D Callaghan; Nicholas A Stella; Regis P Kowalski; Nancy A McNamara; Robert M Q Shanks
Journal:  J Ocul Pharmacol Ther       Date:  2019-10-10       Impact factor: 2.671

4.  Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid.

Authors:  Sunil Vooturi; David Bourne; Jiban Jyoti Panda; Stephanie Choi; Hyewon Kim; Sarath K Yandrapu; Uday B Kompella
Journal:  J Ocul Pharmacol Ther       Date:  2020-07-14       Impact factor: 2.850

5.  Cationic Polyelectrolyte Nanocapsules of Moxifloxacin for Microbial Keratitis Therapy: Development, Characterization, and Pharmacodynamic Study.

Authors:  Parasuraman Mohan; Karthikeyan Kesavan
Journal:  AAPS PharmSciTech       Date:  2021-06-28       Impact factor: 3.246

6.  The effect of pH, dilution, and temperature on the viscosity of ocular lubricants--shift in rheological parameters and potential clinical significance.

Authors:  M Q Rahman; K-S Chuah; E C A Macdonald; J P M Trusler; K Ramaesh
Journal:  Eye (Lond)       Date:  2012-10-19       Impact factor: 3.775

7.  Sodium hyaluronate eyedrops in the treatment of dry eyes.

Authors:  S Shimmura; M Ono; K Shinozaki; I Toda; E Takamura; Y Mashima; K Tsubota
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

8.  Assessment of dry eye signs and symptoms and ocular tolerance of a preservative-free lacrimal substitute (Hylabak®) versus a preserved lacrimal substitute (Systane®) used for 3 months in patients after LASIK.

Authors:  Yuri S Astakhov; Sergei Y Astakhov; Alla B Lisochkina
Journal:  Clin Ophthalmol       Date:  2013-12-09

Review 9.  Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma.

Authors:  Uday B Kompella; Rachel R Hartman; Madhoosudan A Patil
Journal:  Prog Retin Eye Res       Date:  2020-09-04       Impact factor: 21.198

10.  Use of preservative-free hyaluronic acid (Hylabak(®)) for a range of patients with dry eye syndrome: experience in Russia.

Authors:  Vladimir Vsevolodovich Brjesky; Yury Fedorovich Maychuk; Alexey Vladimirovich Petrayevsky; Peter Gerrievich Nagorsky
Journal:  Clin Ophthalmol       Date:  2014-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.